|
US20040028686A1
(en)
*
|
2001-06-28 |
2004-02-12 |
Faulk Ward Page |
Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
|
|
EP2163256B1
(en)
|
2001-05-11 |
2015-09-02 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
CN1463270A
(zh)
|
2001-05-31 |
2003-12-24 |
梅达莱克斯公司 |
细胞毒素、其有用的前体药物、连接基团和稳定剂
|
|
EP1610763A2
(en)
*
|
2003-03-31 |
2006-01-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
|
|
CN1816356A
(zh)
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
|
WO2005042002A2
(en)
*
|
2003-10-30 |
2005-05-12 |
Entelos, Inc. |
Treatment of rhematoid arthritis with flip antagonists
|
|
US20070287680A1
(en)
*
|
2004-05-10 |
2007-12-13 |
University Of Utah Research Foundation |
Combined Active and Passive Targeting of Biologically Active Agents
|
|
MXPA06013413A
(es)
|
2004-05-19 |
2007-01-23 |
Medarex Inc |
Enlazadores quimicos y conjugados de los mismos.
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
AU2005303389A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
|
AU2006213662B2
(en)
|
2005-02-11 |
2010-08-05 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
BRPI0614100A2
(pt)
|
2005-08-03 |
2011-03-09 |
Immunogen Inc |
formulações de imunoconjugado lìquidas
|
|
IL282138B2
(en)
|
2005-08-24 |
2024-01-01 |
Immunogen Inc |
Process for preparing purified drug conjugates
|
|
ES2416136T3
(es)
*
|
2005-09-26 |
2013-07-30 |
Medarex, Inc. |
Conjugados de anticuerpo-fármaco y su uso
|
|
ES2375843T3
(es)
|
2005-10-26 |
2012-03-06 |
Medarex, Inc. |
Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
|
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
ZA200900545B
(en)
|
2006-07-18 |
2010-03-31 |
Sanofi Aventis |
Antagonist antibody against EPHA2 for the treatment of cancer
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
MX338185B
(es)
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
CN101616911A
(zh)
|
2007-02-21 |
2009-12-30 |
梅达莱克斯公司 |
具有单个氨基酸的化学连接物及其偶联物
|
|
EP2134854B1
(en)
|
2007-03-15 |
2015-04-15 |
Ludwig Institute for Cancer Research Ltd. |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
|
KR102339457B1
(ko)
|
2007-09-26 |
2021-12-14 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
US8742076B2
(en)
*
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
|
FR2933702A1
(fr)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
AR072804A1
(es)
|
2008-07-15 |
2010-09-22 |
Genentech Inc |
Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
|
|
MA33210B1
(fr)
|
2009-03-25 |
2012-04-02 |
Genentech Inc |
Nouveaux anticorps anti-a5b1 et leurs utilisations
|
|
RS58810B1
(sr)
|
2009-06-03 |
2019-07-31 |
Immunogen Inc |
Metodi konjugacije
|
|
JP6091894B2
(ja)
|
2009-09-16 |
2017-03-15 |
ジェネンテック， インコーポレイテッド |
コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
|
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
|
EP2486023A4
(en)
|
2009-10-06 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
PT2949670T
(pt)
|
2009-12-10 |
2019-05-20 |
Hoffmann La Roche |
Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
|
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック， インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
WO2011107553A1
(en)
|
2010-03-05 |
2011-09-09 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
KR101899835B1
(ko)
|
2010-03-24 |
2018-09-19 |
제넨테크, 인크. |
항-ｌｒｐ６ 항체
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
KR101885388B1
(ko)
|
2010-06-18 |
2018-08-03 |
제넨테크, 인크. |
항-Ａｘｌ 항체 및 사용 방법
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
|
RU2013110844A
(ru)
|
2010-08-13 |
2014-09-20 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
|
|
RU2584597C2
(ru)
|
2010-08-13 |
2016-05-20 |
Рош Гликарт Аг |
Антитела против а2 тенасцина с и способы их применения
|
|
ES2655616T3
(es)
|
2010-08-13 |
2018-02-20 |
Roche Glycart Ag |
Anticuerpos anti-FAP y procedimientos de uso
|
|
AU2011295919A1
(en)
|
2010-08-31 |
2013-03-07 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
US8772457B2
(en)
|
2010-11-10 |
2014-07-08 |
Genentech, Inc. |
BACE1 antibodies
|
|
BR112013013127B1
(pt)
|
2010-12-02 |
2021-06-22 |
Nerviano Medical Sciences S.R.L. |
Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos
|
|
WO2012083132A2
(en)
|
2010-12-16 |
2012-06-21 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
|
SG191219A1
(en)
|
2010-12-22 |
2013-07-31 |
Genentech Inc |
Anti-pcsk9 antibodies and methods of use
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012135517A2
(en)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
SMT201900114T1
(it)
|
2011-03-29 |
2019-02-28 |
Immunogen Inc |
Preparazione di coniugati maytansinoide-anticorpo mediante un processo a fase unica
|
|
HUE041335T2
(hu)
|
2011-03-29 |
2019-05-28 |
Roche Glycart Ag |
Antitest FC-variánsok
|
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
|
AU2012244816B2
(en)
|
2011-04-20 |
2015-12-10 |
Roche Glycart Ag |
Method and constructs for the pH dependent passage of the blood-brain-barrier
|
|
LT2710035T
(lt)
|
2011-05-16 |
2017-06-26 |
F. Hoffmann-La Roche Ag |
Fgfr1 agonistai ir jų naudojimo būdai
|
|
EP2717916B1
(en)
|
2011-06-10 |
2017-03-08 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
MX356947B
(es)
|
2011-08-23 |
2018-06-20 |
Roche Glycart Ag |
Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
|
|
CN103781801B
(zh)
|
2011-08-23 |
2018-02-09 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
|
MX2014003094A
(es)
|
2011-09-15 |
2014-04-25 |
Genentech Inc |
Metodos para promover diferenciacion.
|
|
KR20140064971A
(ko)
|
2011-09-19 |
2014-05-28 |
제넨테크, 인크. |
c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
|
|
HK1200850A1
(en)
|
2011-09-23 |
2015-08-14 |
罗氏格黎卡特股份公司 |
Bispecific anti-egfr/anti igf-1r antibodies
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
LT2766393T
(lt)
|
2011-10-14 |
2018-10-10 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš htra1 ir jų naudojimo būdai
|
|
MX355128B
(es)
|
2011-10-14 |
2018-04-06 |
Genentech Inc |
Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
|
|
EP2766000A2
(en)
|
2011-10-15 |
2014-08-20 |
F.Hoffmann-La Roche Ag |
Scd1 antagonists for treating cancer
|
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
IN2014DN05885A
(enExample)
|
2012-01-18 |
2015-06-05 |
Hoffmann La Roche |
|
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック， インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
|
WO2013120056A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
|
BR112014018005B1
(pt)
|
2012-02-15 |
2021-06-29 |
F. Hoffmann-La Roche Ag |
Uso de um complexo não covalente imobilizado
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
JP2015516980A
(ja)
|
2012-04-26 |
2015-06-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体とベンダムスチンとの併用
|
|
US9056910B2
(en)
|
2012-05-01 |
2015-06-16 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
US8992915B2
(en)
|
2012-05-16 |
2015-03-31 |
Boehringer Ingelheim International Gmbh |
Combination of CD37 antibodies with ICE
|
|
EP2849783A1
(en)
|
2012-05-16 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Combination of cd37 antibodies with further agents
|
|
WO2013184514A1
(en)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
EP2861624A1
(en)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
MX2014014804A
(es)
|
2012-06-27 |
2015-02-12 |
Hoffmann La Roche |
Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
|
|
WO2014001326A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
|
CN104395339A
(zh)
|
2012-06-27 |
2015-03-04 |
弗·哈夫曼-拉罗切有限公司 |
用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
|
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
|
AU2013285422B2
(en)
|
2012-07-04 |
2017-04-27 |
F. Hoffmann-La Roche Ag |
Covalently linked antigen-antibody conjugates
|
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
|
AR091701A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos anti-cd22 e inmunoconjugados
|
|
KR20150030698A
(ko)
|
2012-07-09 |
2015-03-20 |
제넨테크, 인크. |
항-cd79b 항체를 포함하는 면역접합체
|
|
MX361337B
(es)
|
2012-07-13 |
2018-12-04 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
|
|
NZ707091A
(en)
|
2012-10-04 |
2018-12-21 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
US10087250B2
(en)
|
2012-10-08 |
2018-10-02 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
|
MA38176A1
(fr)
|
2012-11-13 |
2017-06-30 |
Genentech Inc |
Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
|
|
WO2014080251A1
(en)
|
2012-11-24 |
2014-05-30 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
AU2013359506B2
(en)
|
2012-12-10 |
2018-05-24 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
EP2931316B1
(en)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
SI2953976T1
(sl)
|
2013-02-08 |
2021-08-31 |
Novartis Ag |
Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
HK1211235A1
(en)
|
2013-02-22 |
2016-05-20 |
霍夫曼-拉罗奇有限公司 |
Methods of treating cancer and preventing drug resistance
|
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
|
WO2014159835A1
(en)
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
EA035253B1
(ru)
|
2013-03-15 |
2020-05-21 |
Новартис Аг |
Лекарственные конъюгаты антител
|
|
RU2661111C2
(ru)
|
2013-03-15 |
2018-07-11 |
Ац Иммуне С.А. |
Антитела к тау и способы применения
|
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
AR095517A1
(es)
|
2013-03-15 |
2015-10-21 |
Genentech Inc |
ANTICUERPOS CONTRA EL RECEPTOR QUIMIOATRAYENTE EXPRESADO EN CÉLULAS T HELPER 2 (ANTI-CRTh2) Y MÉTODOS DE USO
|
|
HK1211963A1
(en)
|
2013-03-15 |
2016-06-03 |
豪夫迈．罗氏有限公司 |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
KR20220053691A
(ko)
|
2013-03-15 |
2022-04-29 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
US20160068613A1
(en)
|
2013-04-29 |
2016-03-10 |
Hoffmann-La Roche Inc. |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
PH12021550015A1
(en)
|
2013-05-20 |
2022-05-11 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
|
EA032231B1
(ru)
|
2013-10-11 |
2019-04-30 |
Мерсана Терапьютикс, Инк. |
Конъюгаты белок-полимер-лекарственное средство
|
|
WO2015054669A1
(en)
|
2013-10-11 |
2015-04-16 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
|
BR112016008477A2
(pt)
|
2013-10-18 |
2017-10-03 |
Genentech Inc |
Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
|
RU2689388C1
(ru)
|
2013-12-16 |
2019-05-28 |
Дженентек, Инк. |
Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
ES2895752T3
(es)
|
2014-01-03 |
2022-02-22 |
Hoffmann La Roche |
Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
|
|
CN105873616B
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
共价连接的多肽毒素-抗体缀合物
|
|
KR102278979B1
(ko)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
|
|
US9518121B2
(en)
|
2014-02-12 |
2016-12-13 |
Genentech, Inc. |
Anti-Jagged1 antibodies and methods of use
|
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
PT3122757T
(pt)
|
2014-02-28 |
2023-11-03 |
Hangzhou Dac Biotech Co Ltd |
Ligantes carregados e as suas utilizações em conjugação
|
|
EP3960767A3
(en)
|
2014-03-12 |
2022-06-01 |
Novartis AG |
Specific sites for modifying antibodies to make immunoconjugates
|
|
MX2016011637A
(es)
|
2014-03-14 |
2017-04-13 |
Genentech Inc |
Metodos y composiciones para secrecion de polipeptidos heterologos.
|
|
RU2688349C2
(ru)
|
2014-03-21 |
2019-05-21 |
Ф. Хоффманн-Ля Рош Аг |
In vitro прогнозирование времени полужизни антител in vivo
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
|
AU2015241037B2
(en)
|
2014-03-31 |
2020-10-15 |
Genentech, Inc. |
Anti-OX40 antibodies and methods of use
|
|
BR112016027222A2
(pt)
|
2014-05-22 |
2018-01-30 |
Genentech Inc |
anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
|
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック， インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
|
KR20170026362A
(ko)
|
2014-06-26 |
2017-03-08 |
에프. 호프만-라 로슈 아게 |
항-ｂｒｄｕ 항체 및 사용 방법
|
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
MA40513A
(fr)
|
2014-08-12 |
2017-06-21 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
JP6622293B2
(ja)
*
|
2014-09-12 |
2019-12-18 |
ジェネンテック， インコーポレイテッド |
アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
|
|
CR20170095A
(es)
|
2014-09-12 |
2017-07-19 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
|
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
PE20170935A1
(es)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados
|
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
|
WO2016070062A2
(en)
|
2014-10-31 |
2016-05-06 |
Genentech, Inc. |
Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
|
|
RU2017119231A
(ru)
|
2014-11-03 |
2018-12-06 |
Дженентек, Инк. |
Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
|
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
CN108064244B
(zh)
|
2014-11-14 |
2021-09-17 |
诺华股份有限公司 |
抗体药物缀合物
|
|
CN107001473B
(zh)
|
2014-11-19 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
抗-运铁蛋白受体抗体及使用方法
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック， インコーポレイテッド |
ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
|
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
|
SG11201704449VA
(en)
|
2014-12-05 |
2017-06-29 |
Genentech Inc |
ANTI-CD79b ANTIBODIES AND METHODS OF USE
|
|
CA2966365A1
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
MY181199A
(en)
|
2014-12-19 |
2020-12-21 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
TWI617580B
(zh)
|
2014-12-19 |
2018-03-11 |
中外製藥股份有限公司 |
抗ｃ５抗體及使用方法
|
|
AR103442A1
(es)
|
2015-01-16 |
2017-05-10 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígenos quiméricos específicos de ror1
|
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
|
|
CN115932273A
(zh)
|
2015-04-24 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
EP4450524A3
(en)
|
2015-05-11 |
2025-05-14 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック， インコーポレイテッド |
癌のための治療方法及び診断方法
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
CN107847568B
(zh)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
抗cll-1抗体和使用方法
|
|
EP3310814B1
(en)
|
2015-06-16 |
2023-08-02 |
F. Hoffmann-La Roche AG |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
KR20180012859A
(ko)
|
2015-06-17 |
2018-02-06 |
제넨테크, 인크. |
항-her2 항체 및 이용 방법
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
CN107531788B
(zh)
|
2015-06-24 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对her2和血脑屏障受体特异性的三特异性抗体及使用方法
|
|
EP3313885A1
(en)
|
2015-06-29 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
CN108449940B
(zh)
|
2015-07-12 |
2021-06-08 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
US10669343B2
(en)
|
2015-08-05 |
2020-06-02 |
Janssen Biotech, Inc. |
Anti-CD154 antibodies and methods of using them
|
|
WO2017025458A1
(en)
|
2015-08-07 |
2017-02-16 |
Gamamabs Pharma |
Antibodies, antibody drug conjugates and methods of use
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
|
CA2999917A1
(en)
|
2015-09-24 |
2017-03-30 |
Abvitro Llc |
Hiv antibody compositions and methods of use
|
|
MY186016A
(en)
|
2015-09-25 |
2021-06-14 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
CN108368510B
(zh)
|
2015-09-30 |
2023-09-01 |
詹森生物科技公司 |
特异性结合人cd40的激动性抗体和使用方法
|
|
CN114057885A
(zh)
|
2015-10-02 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
|
RU2746409C1
(ru)
|
2015-10-02 |
2021-04-13 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к pd1 и способы их применения
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CN114773481B
(zh)
|
2015-10-02 |
2025-04-29 |
豪夫迈·罗氏有限公司 |
对pd1和tim3特异性的双特异性抗体
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
JP6920292B2
(ja)
|
2015-10-30 |
2021-08-18 |
ジェネンテック， インコーポレイテッド |
ヒンジが修飾された抗体断片及び作製方法
|
|
MY198562A
(en)
|
2015-11-03 |
2023-09-05 |
Janssen Biotech Inc |
Antibodies specifically binding pd-1 and their uses
|
|
EP3371217B1
(en)
|
2015-11-08 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Methods of screening for multispecific antibodies
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
KR102850929B1
(ko)
|
2015-12-09 |
2025-08-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
|
WO2017100402A1
(en)
*
|
2015-12-11 |
2017-06-15 |
Archer Daniels Midland Company |
One-pot synthesis of anhydropentitol esters from pentitols, catalyzed by water-tolerant lewis acids
|
|
IL259256B2
(en)
|
2015-12-18 |
2023-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
WO2017104783A1
(en)
|
2015-12-18 |
2017-06-22 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
がんをモニタリングし治療するための方法
|
|
SG11201808994YA
(en)
|
2016-04-15 |
2018-11-29 |
Bioatla Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
|
SG11201809620UA
(en)
|
2016-05-02 |
2018-11-29 |
Hoffmann La Roche |
The contorsbody - a single chain target binder
|
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
|
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EA201990017A1
(ru)
|
2016-06-17 |
2019-07-31 |
Чугаи Сейяку Кабусики Кайся |
Антитела к миостатину и способы их применения
|
|
WO2017221883A1
(ja)
*
|
2016-06-20 |
2017-12-28 |
武田薬品工業株式会社 |
抗体－薬物コンジュゲート
|
|
US20240018268A1
(en)
|
2016-07-29 |
2024-01-18 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-cd19 antibodies
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
JP6527643B2
(ja)
|
2016-08-05 |
2019-06-05 |
中外製薬株式会社 |
Ｉｌ−８関連疾患の治療用又は予防用組成物
|
|
EP3504239B1
(en)
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
JP7579056B2
(ja)
|
2016-10-06 |
2024-11-07 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
WO2018081648A2
(en)
|
2016-10-29 |
2018-05-03 |
Genentech, Inc. |
Anti-mic antibidies and methods of use
|
|
CN110099682B
(zh)
|
2016-11-14 |
2023-03-31 |
杭州多禧生物科技有限公司 |
偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018091724A1
(en)
|
2016-11-21 |
2018-05-24 |
Cureab Gmbh |
Anti-gp73 antibodies and immunoconjugates
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
EP3558360A1
(en)
|
2016-12-22 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
UA126574C2
(uk)
|
2017-02-10 |
2022-11-02 |
Дженентек, Інк. |
Антитіло проти триптази, його композиція та застосування
|
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
KR102769634B1
(ko)
|
2017-04-27 |
2025-02-19 |
테사로, 인코포레이티드 |
림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
JP7320458B2
(ja)
|
2017-06-22 |
2023-08-03 |
メルサナ セラピューティクス インコーポレイテッド |
薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
|
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2019078357A1
(ja)
|
2017-10-20 |
2019-04-25 |
中外製薬株式会社 |
細胞への分子の取り込みを測定する方法
|
|
BR112020007736A2
(pt)
|
2017-10-30 |
2020-10-20 |
F. Hoffmann-La Roche Ag |
composição e método de tratamento
|
|
ES2907054T3
(es)
|
2017-11-01 |
2022-04-21 |
Hoffmann La Roche |
TriFab-Contorsbody
|
|
WO2019089969A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
|
JP7544597B2
(ja)
|
2017-11-06 |
2024-09-03 |
ジェネンテック， インコーポレイテッド |
がんの診断及び療法
|
|
EP3710589A4
(en)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-C1S ANTIBODIES AND METHOD OF USING
|
|
KR20250148679A
(ko)
|
2017-12-06 |
2025-10-14 |
어비디티 바이오사이언시스 인크. |
근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
|
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US20200339686A1
(en)
|
2018-01-16 |
2020-10-29 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CA3089287A1
(en)
|
2018-02-08 |
2019-08-15 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
IL277375B2
(en)
|
2018-03-15 |
2025-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
EP3794022A1
(en)
|
2018-05-14 |
2021-03-24 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
JP7460609B2
(ja)
|
2018-05-14 |
2024-04-02 |
ウェアウルフ セラピューティクス， インコーポレイテッド |
活性化可能なインターロイキン－２ポリペプチド及びその使用方法
|
|
MA52777A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Agents de liaison psma et utilisations correspondantes
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
SG10202106830VA
(en)
|
2018-08-10 |
2021-08-30 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
|
CA3110750A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cd33 and constructs thereof
|
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
|
EP3873534A1
(en)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
TW202035442A
(zh)
|
2018-12-20 |
2020-10-01 |
美商建南德克公司 |
經修飾之抗體Fc及其使用方法
|
|
JP7607564B2
(ja)
|
2018-12-21 |
2024-12-27 |
ノバルティス アーゲー |
Ｐｍｅｌ１７に対する抗体及びその結合体
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
CA3123050A1
(en)
|
2018-12-26 |
2020-07-02 |
City Of Hope |
Activatable masked anti-ctla4 binding proteins
|
|
BR112021014276A2
(pt)
|
2019-01-22 |
2021-09-28 |
Genentech, Inc. |
Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
EP3915581A4
(en)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
|
AU2020236015B9
(en)
|
2019-03-14 |
2024-11-28 |
Genentech, Inc. |
Treatment of cancer with HER2XCD3 bispecific antibodies in combination with anti-HER2 MAB
|
|
WO2020187998A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
|
TW202043291A
(zh)
|
2019-04-19 |
2020-12-01 |
美商建南德克公司 |
抗mertk抗體及使用方法
|
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
|
EP3959319A4
(en)
|
2019-04-25 |
2023-06-07 |
Avidity Biosciences, Inc. |
NUCLEIC ACID COMPOSITIONS AND METHODS FOR MULTI-EXON SKIPPING
|
|
JP7754723B2
(ja)
|
2019-05-14 |
2025-10-15 |
ウェアウルフ セラピューティクス， インコーポレイテッド |
分離部分及びその使用方法
|
|
JP7359864B2
(ja)
|
2019-07-10 |
2023-10-11 |
中外製薬株式会社 |
クローディン６結合分子およびその使用
|
|
MX2022003610A
(es)
|
2019-09-27 |
2022-04-20 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
|
US20230028050A1
(en)
|
2019-12-06 |
2023-01-26 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
AR120741A1
(es)
|
2019-12-13 |
2022-03-16 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso
|
|
UA128549C2
(uk)
|
2019-12-27 |
2024-08-07 |
Чугаі Сейяку Кабусікі Кайся |
Антитіло до ctla-4 та його застосування
|
|
JP2023509708A
(ja)
|
2020-01-03 |
2023-03-09 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
AU2021205312A1
(en)
|
2020-01-09 |
2022-07-14 |
Mersana Therapeutics, Inc. |
Site specific antibody-drug conjugates with peptide-containing linkers
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
PH12022552371A1
(en)
|
2020-03-13 |
2023-12-18 |
Genentech Inc |
Anti-interleukin-33 antibodies and uses thereof
|
|
WO2021188749A1
(en)
|
2020-03-19 |
2021-09-23 |
Genentech, Inc. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
|
IL296387B2
(en)
|
2020-03-19 |
2024-08-01 |
Avidity Biosciences Inc |
Preparations and methods for the treatment of facial, back and arm muscle atrophy
|
|
MX2022011880A
(es)
|
2020-03-27 |
2022-10-20 |
Avidity Biosciences Inc |
Composiciones y metodos para tratar distrofia muscular.
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
EP4165415A1
(en)
|
2020-06-12 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
BR112022025801A2
(pt)
|
2020-06-18 |
2023-10-03 |
Hoffmann La Roche |
Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
|
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
|
EP4179332A1
(en)
|
2020-07-13 |
2023-05-17 |
Genentech, Inc. |
Cell-based methods for predicting polypeptide immunogenicity
|
|
EP4190801A4
(en)
|
2020-07-29 |
2024-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR MEASURING THE PHARMACOKINETICS OF A DRUG LABELED WITH A NON-RADIOACTIVE SUBSTANCE
|
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
MX2023001441A
(es)
|
2020-08-07 |
2023-03-06 |
Genentech Inc |
Proteinas de fusion del ligando para flt3 y metodos de uso.
|
|
CN115836122A
(zh)
|
2020-08-07 |
2023-03-21 |
基因泰克公司 |
用于预测多肽免疫原性的基于t细胞的方法
|
|
WO2022076462A1
(en)
|
2020-10-05 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
|
JP7716473B2
(ja)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
|
|
IL302217A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
|
|
US11999786B2
(en)
|
2020-11-24 |
2024-06-04 |
Novartis Ag |
Anti-CD48 antibodies, antibody drug conjugates, and uses thereof
|
|
CA3196844A1
(en)
|
2020-11-25 |
2022-06-02 |
Raphael Rozenfeld |
Tumor-specific cleavable linkers
|
|
IL303656A
(en)
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
Anti-hla-g antibodies and use thereof
|
|
PE20240761A1
(es)
|
2021-01-28 |
2024-04-17 |
Janssen Biotech Inc |
Proteinas de union a psma y usos de estas
|
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
KR20230170738A
(ko)
|
2021-04-16 |
2023-12-19 |
노파르티스 아게 |
항체 약물 접합체 및 이의 제조 방법
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
|
|
EP4342984A4
(en)
|
2021-05-19 |
2025-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Method for predicting in vivo pharmacokinetics of molecule
|
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
TWI864408B
(zh)
|
2021-06-25 |
2024-12-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
JP7472405B2
(ja)
|
2021-06-25 |
2024-04-22 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
PE20240727A1
(es)
|
2021-08-27 |
2024-04-15 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos
|
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
MX2024004117A
(es)
|
2021-10-08 |
2024-04-19 |
Chugai Pharmaceutical Co Ltd |
Metodo para preparar formulacion de jeringa precargada.
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
JP2025501522A
(ja)
|
2021-12-17 |
2025-01-22 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体及び使用方法
|
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
KR20230125129A
(ko)
|
2022-02-17 |
2023-08-29 |
주식회사 노벨티노빌리티 |
항체-약물 접합체
|
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
|
JP2025514610A
(ja)
|
2022-03-25 |
2025-05-09 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｍｓｌｎ抗体及び使用方法
|
|
AU2022450448A1
(en)
|
2022-04-01 |
2024-10-10 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
EP4508081A1
(en)
|
2022-04-13 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
AU2023253705A1
(en)
|
2022-04-13 |
2024-10-17 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
|
US20230346862A1
(en)
|
2022-05-02 |
2023-11-02 |
Athanor Biosciences, Inc. |
Cancer eradicating - bio-nanoparticles (ce-bnp)
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2023284422A1
(en)
|
2022-06-07 |
2024-12-19 |
Genentech, Inc. |
Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
|
|
AU2023305619A1
(en)
|
2022-07-13 |
2025-01-23 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
KR20250049569A
(ko)
|
2022-07-15 |
2025-04-11 |
페온 테라퓨틱스 리미티드 |
항체-약물 접합체
|
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CR20250056A
(es)
|
2022-07-22 |
2025-03-19 |
Genentech Inc |
Moléculas de unión al antígeno anti-steap1 y sus usos.
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
EP4609201A1
(en)
|
2022-10-25 |
2025-09-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
KR20250089547A
(ko)
|
2022-10-25 |
2025-06-18 |
펩토믹, 에스.엘. |
암 치료를 위한 조합 요법
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
AR131320A1
(es)
|
2022-12-13 |
2025-03-05 |
Juno Therapeutics Inc |
Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
EP4473974A1
(en)
|
2023-06-07 |
2024-12-11 |
Peptomyc, S.L. |
Omomyc and kras inhibitors combination therapy for the treatment of cancer
|
|
TW202502371A
(zh)
|
2023-06-07 |
2025-01-16 |
瓦爾希伯倫私人腫瘤研究基金會 |
用於治療癌症的與ｂｒａｆ抑制劑的組合療法
|
|
WO2024251846A1
(en)
|
2023-06-07 |
2024-12-12 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with mek inhibitors for the treatment of cancer
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
